HOME >> BIOLOGY >> NEWS
New threat to commercial fishing

Commercial fishing practices can reduce genetic diversity in fish populations, possibly threatening their productivity and adaptability to environmental change, new research has found.

An Australian zoologist now at the University of Melbourne, along with colleagues from the United Kingdom and New Zealand, was the first to record a decline in the genetic diversity of a commercially exploited marine species. Their findings, published in the latest volume of the Proceedings of the National Academy of Sciences, shout a warning that could force a rethink to current fisheries management and the research focus into sustainable fishing.

Dr Greg Adcock analysed the DNA found in scales preserved from two populations of New Zealand snapper collected from the 1950s to 1998. One population had been commercially fished since the late 1800s. The other was a 'virgin' population, being subjected to subsistence and recreational fishing only until the scale collection began.

Adcock and colleagues found that the 'virgin' population from Tasman Bay on New Zealand's South Island had suffered an unexpected decline in genetic diversity, starting from the time it began to be commercially exploited in the 1950s.

The other population, from the North Island's Hauraki Bay, showed no decline in genetic diversity in the nearly 50 years to 1998.

The paper reports that the Tasman Bay's effective population size (the number of fish in the population capable of breeding) is100,000 times fewer than its total number, and several orders of magnitude lower than expected.

"In Tasman Bay, commercial fishing has often reduced total numbers to as low as about one million. This leaves only a few hundred fish to contribute to the next generation, a dangerously low genetic base from which to sustain a population," says Adcock.

"With a high effective population you can retain a large amount of rare genetic variation. Such variation is lost as numbers
'"/>

Contact: Jason Major
jmajor@unimelb.edu.au
61-3-8344-0181
University of Melbourne
13-Aug-2002


Page: 1 2 3

Related biology news :

1. Scientists decipher genetic code of biothreat pathogen
2. Identifying tick genes could halt disease, bioterrorism threat
3. UC Irvine scientists to develop vaccine to combat bioterrorism threat from deadly bacteria
4. Increasing international insect threat to stored food
5. Report outlines steps needed to lessen smallpox threat
6. Computer model shows increased US threat from soybean rust
7. Danger spots identified for threatened grizzly bear
8. 51 globally threatened species get new lease on life in the Caucasus
9. Disease threatens cucumbers, pumpkins, and other vine crops
10. Urban runoff poses increased health threat for surfers, other beach users, UCI study shows
11. City rain run-off poses threat to coastal water users

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New threat commercial fishing

(Date:5/19/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Genetic Testing Market Outlook 2018 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
(Date:5/21/2015)... , May 21, 2015  The EveryLife ... Hatch (R-UT) and Amy Klobuchar ... Now Accelerating Cures & Treatments, or OPEN ACT. ... disease patient advocacy organizations, this bipartisan legislation promises ... affordable medicines to rare disease patients by incentivizing ...
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Veolia’s ... an exclusive North American distribution agreement with VWR ... system. , With more than 160 years of ... and services for laboratory and production facilities, has ... excellence and differentiated services to enable science. ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 This year ... especially for lawns. US Patented Pearl’s Premium Ultra ... lawns around the country that are coming out of ... addresses a number of major global concerns related to ... “non-grass” grass – the alternative to the standard, water-wasting, ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2
Cached News: